We cover transcatheter embolisation and occlusion (TEO) pretty often on our pages, which hints at the fact that it’s a rapidly developing technology field. As a bit of background it’s interesting, therefore, to see that market intelligence company Millennium Research Group, reckons the U.S. TEO device market will grow at an average annual rate of just over nine percent through 2016, driven by an aging population and a trend away from traditional surgical procedures and toward minimally invasive procedures, with particular growth in aneurysm treatment.
Minimally invasive procedures have been growing rapidly in the United States in both the peripheral vascular and interventional neuroradiology indications. The uptake has been particularly strong in the treatment of aneurysms. The standard treatment for aneurysms has long been surgical clipping, but as of 2011 a significant majority of aneurysm procedures used endovascular techniques such as coiling, stent-assisted coiling, treatment with liquid embolics and treatment with flow-diverting devices.
Interventional neuroradiology (INR) flow-diverting devices, in fact, are the fastest-growing segment among transcatheter embolisation and occlusion devices in the US. These devices could represent a universal solution for the most difficult to treat aneurysm cases, such as fusiform, wide-neck, giant and multilobar aneurysms. Though they cost more per unit, they tend to be cost-effective overall when compared to alternative treatments for giant or wide-necked aneurysms, such as stent-assisted coiling. Currently, only ev3 (a Covidien company) has a flow-diverting device on the US market, the Pipeline Embolization Device, typically called just the Pipeline.
“Physicians are excited to add INR flow-diverting devices to their toolbox,” said MRG Analyst Sean Messenger. “In our interviews with them, they cited the advantages of aneurysm shrinkage, which does not happen with coils, shorter procedure times, and procedure simplicity. The willingness of interventional radiologists to try new technologies will lead to strong uptake of these devices. By penetrating into the endovascular aneurysm treatment market and increasing the overall treatable patient population this segment of the market will grow at an average annual rate of almost 35 percent.”
Source: US Markets for Transcatheter Embolization and Occlusion Devices 2012, Millennium Research Group